Yip-Schneider et al. showed that the combination of DMAPT and gemcitabine significantly decreased the multiplicity and incidence of pancreatic adenocarcinomas by reducing the levels of eotaxin, tumor necrosis factor-alpha (TNF-α), macrophage inflammatory protein-1 beta (MIP-1β), inflammatory cytokines IL-12p40, and monocyte chemotactic protein-1 (MCP-1), all of which are NF-κB target genes [18]. This evidence concerns the gene CCL2 and pancreatic adenocarcinoma.